Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Loperamide | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Loperamide | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Loperamide | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Loperamide | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Loperamide | hsa00230 | Purine metabolism | 4.60E-02 | 4 | Q13370, P36959, Q13956, P27707 | PDE3B, GMPR, PDE6H, DCK | More | | Loperamide | hsa00240 | Pyrimidine metabolism | 4.50E-02 | 2 | P32320, P27707 | CDA, DCK | More | | Loperamide | hsa00500 | Starch and sucrose metabolism | 9.77E-06 | 4 | O43451, P46976, P35573, P06737 | MGAM, GYG1, AGL, PYGL | More | | Loperamide | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Loperamide | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | Loperamide | hsa00534 | Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 4.77E-02 | 1 | Q7LGA3 | HS2ST1 | More | | Loperamide | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Loperamide | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Loperamide | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Loperamide | hsa00670 | One carbon pool by folate | 3.99E-02 | 2 | O95954, Q99707 | FTCD, MTR | More | | Loperamide | hsa00730 | Thiamine metabolism | 7.19E-04 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Loperamide | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Loperamide | hsa00920 | Sulfur metabolism | 3.01E-02 | 1 | O95571 | ETHE1 | More | | Loperamide | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.58E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Loperamide | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Loperamide | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Loperamide | hsa00983 | Drug metabolism - other enzymes | 8.82E-04 | 4 | P20839, P32320, P05164, Q16772 | IMPDH1, CDA, MPO, GSTA3 | More | | Loperamide | hsa01100 | Metabolic pathways | 3.95E-02 | 23 | Q9Y234, Q99707, P29218, P11310, P27707, Q13370, P36959, Q13956, P30043, Q02252, O60701, O14772, O95954, Q02318, P04406, O15466, P09960, Q9P2R7, Q9UHY7, P35573, Q13488, Q16718, Q02809 | LIPT1, MTR, IMPA1, ACADM, DCK, PDE3B, GMPR, PDE6H, BLVRB, ALDH6A1, UGDH, FPGT, FTCD, CYP27A1, GAPDH, ST8SIA5, LTA4H, SUCLA2, ENOPH1, AGL, TCIRG1, NDUFA5, PLOD1 | More | | Loperamide | hsa01524 | Platinum drug resistance | 1.97E-04 | 7 | P10415, Q13489, O15392, P78417, P23025, P11388, P43246 | BCL2, BIRC3, BIRC5, GSTO1, XPA, TOP2A, MSH2 | More | | Loperamide | hsa02010 | ABC transporters | 1.99E-04 | 4 | P45844, P08183, Q8IZY2, Q99758 | ABCG1, ABCB1, ABCA7, ABCA3 | More | | Loperamide | hsa03008 | Ribosome biogenesis in eukaryotes | 2.60E-03 | 5 | Q9NYH9, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, RPP38, GNL3, NVL, NXF2; NXF2B | More | | Loperamide | hsa03013 | RNA transport | 1.14E-05 | 15 | P62826, O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, P63279, Q14152, O75822, P78345, Q14240, Q9Y6A5, P51114 | RAN, XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, UBE2I, EIF3A, EIF3J, RPP38, EIF4A2, TACC3, FXR1 | More | | Loperamide | hsa03015 | mRNA surveillance pathway | 3.62E-02 | 3 | O43148, P61326, P52298 | RNMT, MAGOH, NCBP2 | More | | Loperamide | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Loperamide | hsa03020 | RNA polymerase | 9.86E-07 | 2 | Q9GZM3, P52435 | POLR2J2, POLR2J | More | | Loperamide | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Loperamide | hsa03040 | Spliceosome | 2.95E-09 | 21 | Q14562, O43143, O60508, Q99633, P17844, O14776, P08579, O75940, P52298, P09651, Q15365, O75494, Q13595, Q07955, Q01130, Q13243, Q9UMS4, P11142, O95777, O43447, P61326 | DHX8, DHX15, CDC40, PRPF18, DDX5, TCERG1, SNRPB2, SMNDC1, NCBP2, HNRNPA1, PCBP1, FUSIP1, TRA2A, SFRS1, SFRS2, SFRS5, PRPF19, HSPA8, LSM8, PPIH, MAGOH | More | | Loperamide | hsa03050 | Proteasome | 5.53E-03 | 2 | P43686, P28070 | PSMC4, PSMB4 | More | | Loperamide | hsa03320 | PPAR signaling pathway | 2.18E-02 | 2 | O00767, Q02318 | SCD, CYP27A1 | More | | Loperamide | hsa03460 | Fanconi anemia pathway | 3.70E-03 | 3 | Q9NPI8, O60673, Q9UNA4 | FANCF, REV3L, POLI | More | | Loperamide | hsa04014 | Ras signaling pathway | 2.65E-03 | 9 | P31751, P20827, P49767, Q13009, P17252, Q15311, P0DP23, P62873, P19174 | AKT2, EFNA1, VEGFC, TIAM1, PRKCA, RALBP1, CALM1, GNB1, PLCG1 | More | | Loperamide | hsa04015 | Rap1 signaling pathway | 3.68E-04 | 11 | P20827, P49767, P63261, P25116, Q13009, Q08828, P51828, P31751, P0DP23, P17252, P19174 | EFNA1, VEGFC, ACTG1, F2R, TIAM1, ADCY1, ADCY7, AKT2, CALM1, PRKCA, PLCG1 | More | | Loperamide | hsa04020 | Calcium signaling pathway | 7.15E-09 | 13 | P27987, Q08828, Q16566, Q13557, P17252, O15399, P19174, P25116, P61073, P0DP23, P51828, P23634, P49767 | ITPKB, ADCY1, CAMK4, CAMK2D, PRKCA, GRIN2D, PLCG1, F2R, CXCR4, CALM1, ADCY7, ATP2B4, VEGFC | More | | Loperamide | hsa04024 | cAMP signaling pathway | 3.17E-04 | 11 | Q08828, P51828, P31751, P0DP23, P23634, Q16566, Q13557, Q13370, O15399, P25116, Q13009 | ADCY1, ADCY7, AKT2, CALM1, ATP2B4, CAMK4, CAMK2D, PDE3B, GRIN2D, F2R, TIAM1 | More | | Loperamide | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Loperamide | hsa04062 | Chemokine signaling pathway | 2.36E-05 | 23 | P51684, P25024, P25025, P09341, P19875, Q8NHW4, P47992, Q9UBD3, P07948, P42338, P19174, P62873, P63218, P50151, P49407, Q08881, Q08828, P51828, Q13009, P14598, P42224, P31751, P49841 | CCR6, CXCR1, CXCR2, CXCL1, CXCL2, CCL4L2, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNB1, GNG5, GNG10, ARRB1, ITK, ADCY1, ADCY7, TIAM1, NCF1, STAT1, AKT2, GSK3B | More | | Loperamide | hsa04064 | NF-kappa B signaling pathway | 2.69E-06 | 19 | P10415, Q13489, P51617, Q13546, P14778, P01584, P29965, P19174, Q04759, Q9UDY8, Q13077, P06239, P24522, O75293, Q8NHW4, P09341, P19875, Q06643, Q9NQC7 | BCL2, BIRC3, IRAK1, RIPK1, IL1R1, IL1B, CD40LG, PLCG1, PRKCQ, MALT1, TRAF1, LCK, GADD45A, GADD45B, CCL4L2, CXCL1, CXCL2, LTB, CYLD | More | | Loperamide | hsa04070 | Phosphatidylinositol signaling system | 6.70E-05 | 8 | P19174, P0DP23, Q14643, P23743, P48426, O14732, P27987, P17252 | PLCG1, CALM1, ITPR1, DGKA, PIP4K2A, IMPA2, ITPKB, PRKCA | More | | Loperamide | hsa04071 | Sphingolipid signaling pathway | 1.57E-06 | 12 | P17252, Q9H228, P01375, Q13510, Q13362, Q16537, Q9BX95, Q16539, P04637, P10415, Q9UQC2, P01042 | PRKCA, EDG8, TNF, ASAH1, PPP2R5C, PPP2R5E, SGPP1, MAPK14, TP53, BCL2, GAB2, KNG1 | More | | Loperamide | hsa04072 | Phospholipase D signaling pathway | 2.68E-03 | 12 | P31751, P42338, P43657, P25024, P25025, P19174, P17252, Q15438, Q08828, P51828, P23743, P00734 | AKT2, PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1, PRKCA, PSCD1, ADCY1, ADCY7, DGKA, F2 | More | | Loperamide | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Loperamide | hsa04140 | Autophagy - animal | 2.58E-02 | 7 | P31751, Q7L523, Q96RR4, O75460, P10415, Q96GC9, Q8TEV9 | AKT2, RRAGA, CAMKK2, ERN1, BCL2, TMEM49, SMCR8 | More | | Loperamide | hsa04144 | Endocytosis | 8.99E-03 | 12 | P11142, Q9H444, O43633, O75351, Q9NZZ3, Q15438, Q14161, P14784, Q96QK1, Q9UMY4, Q9Y5X3, Q9UNH7 | HSPA8, CHMP4B, CHMP2A, VPS4B, CHMP5, PSCD1, GIT2, IL2RB, VPS35, SNX12, SNX5, SNX6 | More | | Loperamide | hsa04145 | Phagosome | 3.63E-04 | 10 | P60709, P63261, Q15075, Q15080, P14598, Q13509, P68371, Q13488, O60603, P27824 | ACTB, ACTG1, EEA1, NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, TLR2, CANX | More | | Loperamide | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | | Loperamide | hsa04151 | PI3K-Akt signaling pathway | 4.68E-03 | 18 | O43521, P27348, P20827, P49767, Q13362, P08238, P62873, P16144, P48551, P14784, P23458, P01568, P15336, P18848, P10415, P17252, Q16513, Q6ZUJ8 | BCL2L11, YWHAQ, EFNA1, VEGFC, PPP2R5C, HSP90AB1, GNB1, ITGB4, IFNAR2, IL2RB, JAK1, IFNA21, ATF2, ATF4, BCL2, PRKCA, PKN2, PIK3AP1 | More | | Loperamide | hsa04210 | Apoptosis | 7.52E-04 | 7 | O76075, P07384, P01375, Q9NR28, Q16548, P60709, P63261 | DFFB, CAPN1, TNF, DIABLO, BCL2A1, ACTB, ACTG1 | More | | Loperamide | hsa04213 | Longevity regulating pathway - multiple species | 4.41E-03 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Loperamide | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Loperamide | hsa04217 | Necroptosis | 2.92E-09 | 19 | P01375, P01568, P23458, P48023, Q13489, Q9NQC7, P42224, Q14765, P08238, P01584, P0C0S5, Q6FI13, Q99878, P10415, Q13557, Q9H444, O43633, Q9NZZ3, O75351 | TNF, IFNA21, JAK1, FASLG, BIRC3, CYLD, STAT1, STAT4, HSP90AB1, IL1B, H2AFZ, H2AC18; H2AC19, H2AC14, BCL2, CAMK2D, CHMP4B, CHMP2A, CHMP5, VPS4B | More | | Loperamide | hsa04260 | Cardiac muscle contraction | 4.02E-02 | 2 | P09493, P14927 | TPM1, UQCRB | More | | Loperamide | hsa04261 | Adrenergic signaling in cardiomyocytes | 5.10E-07 | 13 | P09493, Q08828, P51828, P31751, P18848, Q13362, Q16537, P0DP23, Q13557, P17252, P10415, P20020, P23634 | TPM1, ADCY1, ADCY7, AKT2, ATF4, PPP2R5C, PPP2R5E, CALM1, CAMK2D, PRKCA, BCL2, ATP2B1, ATP2B4 | More | | Loperamide | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Loperamide | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Loperamide | hsa04360 | Axon guidance | 8.44E-04 | 8 | P61073, P16333, P20827, O95631, P17252, Q13557, P23528, P19174 | CXCR4, NCK1, EFNA1, NTN1, PRKCA, CAMK2D, CFL1, PLCG1 | More | | Loperamide | hsa04371 | Apelin signaling pathway | 3.08E-02 | 7 | P62873, P31751, Q08828, P51828, Q13370, Q13485, P0DP23 | GNB1, AKT2, ADCY1, ADCY7, PDE3B, SMAD4, CALM1 | More | | Loperamide | hsa04380 | Osteoclast differentiation | 4.18E-02 | 7 | Q9NQC7, Q9UQC2, P23458, P42224, P01584, Q15080, P14598 | CYLD, GAB2, JAK1, STAT1, IL1B, NCF4, NCF1 | More | | Loperamide | hsa04390 | Hippo signaling pathway | 8.78E-05 | 7 | P60709, P63261, P84022, Q13485, Q9UJU2, O43623, Q13489 | ACTB, ACTG1, SMAD3, SMAD4, LEF1, SNAI2, BIRC3 | More | | Loperamide | hsa04510 | Focal adhesion | 3.70E-03 | 8 | P16144, O75369, Q15942, P17252, Q13489, P10415, P49767, P63261 | ITGB4, FLNB, ZYX, PRKCA, BIRC3, BCL2, VEGFC, ACTG1 | More | | Loperamide | hsa04520 | Adherens junction | 1.85E-03 | 5 | Q13485, Q9UJU2, O43623, P60709, P63261 | SMAD4, LEF1, SNAI2, ACTB, ACTG1 | More | | Loperamide | hsa04530 | Tight junction | 6.83E-04 | 6 | P60709, P63261, P16989, P56750, Q14247, P60660 | ACTB, ACTG1, CSDA, CLDN17, CTTN, MYL6 | More | | Loperamide | hsa04540 | Gap junction | 5.21E-03 | 5 | P17252, Q13509, P68371, Q08828, P51828 | PRKCA, TUBB3, TUBB2C, ADCY1, ADCY7 | More | | Loperamide | hsa04610 | Complement and coagulation cascades | 6.30E-07 | 2 | P00734, P0C0L4 | F2, C4A | More | | Loperamide | hsa04611 | Platelet activation | 2.61E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Loperamide | hsa04612 | Antigen processing and presentation | 7.38E-04 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Loperamide | hsa04613 | Neutrophil extracellular trap formation | 2.75E-08 | 26 | P17252, P11215, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P04908, Q6FI13, Q93077, P58876, P62807, P33778, Q16778, O60814, P68431, P14598, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | PRKCA, ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST1H2BC, H2BC3, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P51684 | CCR6 | C-C chemokine receptor type 6 | P17252 | PRKCA | Protein kinase C alpha type | 0.738 | O15245 | SLC22A1 | Solute carrier family 22 member 1 | P11215 | ITGAM | Integrin alpha-M | 0.706 | P22748 | CA4 | Carbonic anhydrase 4 | O60603 | TLR2 | Toll-like receptor 2 | 0.919 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O60603 | TLR2 | Toll-like receptor 2 | 0.867 | P51684 | CCR6 | C-C chemokine receptor type 6 | O60603 | TLR2 | Toll-like receptor 2 | -0.767 | P22748 | CA4 | Carbonic anhydrase 4 | P05164 | MPO | Myeloperoxidase | 0.826 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P05164 | MPO | Myeloperoxidase | 0.711 | P22748 | CA4 | Carbonic anhydrase 4 | P08246 | ELA2 | Neutrophil elastase | 0.921 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P08246 | ELA2 | Neutrophil elastase | 0.703 | P51684 | CCR6 | C-C chemokine receptor type 6 | P08246 | ELA2 | Neutrophil elastase | -0.706 | P22748 | CA4 | Carbonic anhydrase 4 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.856 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.825 | O15245 | SLC22A1 | Solute carrier family 22 member 1 | Q13547 | HDAC1 | Histone deacetylase 1 | -0.711 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13547 | HDAC1 | Histone deacetylase 1 | -0.742 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q92769 | HDAC2 | Histone deacetylase 2 | -0.746 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q92769 | HDAC2 | Histone deacetylase 2 | 0.702 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | P04908 | H2AC4; H2AC8 | Histone H2A type 1-B/E | 0.734 | P22748 | CA4 | Carbonic anhydrase 4 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | 0.866 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | -0.86 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.737 | P11712 | CYP2C9 | Cytochrome P450 2C9 | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.754 | O15245 | SLC22A1 | Solute carrier family 22 member 1 | P58876 | H2BC5 | Histone H2B type 1-D | 0.947 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | P51684 | CCR6 | C-C chemokine receptor type 6 | P33778 | H2BC3 | Histone H2B type 1-B | 0.704 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | O15245 | SLC22A1 | Solute carrier family 22 member 1 | Q16778 | HIST2H2BE | Histone H2B type 2-E | 0.793 | O15245 | SLC22A1 | Solute carrier family 22 member 1 | O60814 | H2BC12 | Histone H2B type 1-K | 0.72 | P11712 | CYP2C9 | Cytochrome P450 2C9 | O60814 | H2BC12 | Histone H2B type 1-K | 0.728 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.913 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.845 | P51684 | CCR6 | C-C chemokine receptor type 6 | P14598 | NCF1 | Neutrophil cytosol factor 1 | -0.713 | P22748 | CA4 | Carbonic anhydrase 4 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.951 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.764 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | -0.803 | P22748 | CA4 | Carbonic anhydrase 4 | P20160 | AZU1 | Azurocidin | 0.747 | P22748 | CA4 | Carbonic anhydrase 4 | P08311 | CTSG | Cathepsin G | 0.717 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P08311 | CTSG | Cathepsin G | 0.709 | P22748 | CA4 | Carbonic anhydrase 4 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.81 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.893 | P22748 | CA4 | Carbonic anhydrase 4 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.826 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 1 | P22748 | CA4 | Carbonic anhydrase 4 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.895 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.842 | P51684 | CCR6 | C-C chemokine receptor type 6 | P21462 | FPR1 | fMet-Leu-Phe receptor | -0.7 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | O43315 | AQP9 | Aquaporin-9 | -0.764 | P22748 | CA4 | Carbonic anhydrase 4 | O43315 | AQP9 | Aquaporin-9 | 0.771 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O43315 | AQP9 | Aquaporin-9 | 0.915 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | -0.744 | P22748 | CA4 | Carbonic anhydrase 4 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.767 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 |
| Loperamide | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Loperamide | hsa04620 | Toll-like receptor signaling pathway | 1.33E-02 | 5 | P51617, P01568, P31751, P42224, Q8NHW4 | IRAK1, IFNA21, AKT2, STAT1, CCL4L2 | More | | Loperamide | hsa04621 | NOD-like receptor signaling pathway | 3.16E-02 | 9 | P01584, P08238, P23458, P42224, P01568, Q9H3M7, Q13489, P43490, P10415 | IL1B, HSP90AB1, JAK1, STAT1, IFNA21, TXNIP, BIRC3, PBEF1, BCL2 | More | | Loperamide | hsa04623 | Cytosolic DNA-sensing pathway | 4.25E-02 | 2 | P01568, Q8NHW4 | IFNA21, CCL4L2 | More | | Loperamide | hsa04625 | C-type lectin receptor signaling pathway | 4.80E-02 | 6 | Q9ULY5, P20749, Q14643, P01375, Q13191, Q16539 | CLEC4E, BCL3, ITPR1, TNF, CBLB, MAPK14 | More | | Loperamide | hsa04630 | JAK-STAT signaling pathway | 1.16E-02 | 8 | P31751, P10415, P42224, P23458, P14784, P16871, Q13651, P01568 | AKT2, BCL2, STAT1, JAK1, IL2RB, IL7R, IL10RA, IFNA21 | More | | Loperamide | hsa04640 | Hematopoietic cell lineage | 5.48E-05 | 15 | P13612, P08514, P21926, P14778, P27930, P11215, P15144, P11836, P25063, P07766, P09693, P01732, P09564, P13765, P01375 | ITGA4, ITGA2B, CD9, IL1R1, IL1R2, ITGAM, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD7, HLA-DOB, TNF | More | | Loperamide | hsa04650 | Natural killer cell mediated cytotoxicity | 6.36E-08 | 13 | P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, P26715 | PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.809 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.81 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.856 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.879 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.893 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.838 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.838 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| Loperamide | hsa04657 | IL-17 signaling pathway | 6.19E-04 | 8 | O00463, Q16539, P49841, P09341, P14780, Q9UJX4, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, ANAPC5, LCN2, TNF | More | | Loperamide | hsa04658 | Th1 and Th2 cell differentiation | 8.90E-06 | 13 | Q04759, P07766, P20963, P09693, Q16539, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Loperamide | hsa04659 | Th17 cell differentiation | 3.31E-05 | 15 | P25963, Q04759, Q16539, P19174, P06239, P14784, P13765, P14778, Q9UL17, P23771, P84022, Q13485, P07766, P09693, P20963 | NFKBIA, PRKCQ, MAPK14, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD3, SMAD4, CD3E, CD3G, CD247 | More | | Loperamide | hsa04660 | T cell receptor signaling pathway | 7.17E-07 | 14 | P01375, Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q04759 | PRKCQ | Protein kinase C theta type | -0.762 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.806 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.812 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.815 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | Q13547 | HDAC1 | Histone deacetylase 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.816 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.816 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.806 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.816 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.781 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| Loperamide | hsa04662 | B cell receptor signaling pathway | 3.68E-02 | 2 | P25963, P20023 | NFKBIA, CR2 | More | | Loperamide | hsa04666 | Fc gamma R-mediated phagocytosis | 2.00E-03 | 8 | P08575, P19174, P23528, P49006, P06396, Q9UQC2, P14598, P17252 | PTPRC, PLCG1, CFL1, MARCKSL1, GSN, GAB2, NCF1, PRKCA | More | | Loperamide | hsa04670 | Leukocyte transendothelial migration | 4.07E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Loperamide | hsa04713 | Circadian entrainment | 5.61E-05 | 7 | O15399, P0DP23, Q13557, P17252, P62873, Q08828, P51828 | GRIN2D, CALM1, CAMK2D, PRKCA, GNB1, ADCY1, ADCY7 | More | | Loperamide | hsa04714 | Thermogenesis | 3.66E-05 | 8 | Q16539, P15336, P60709, P63261, P33121, Q16718, O14521, P36542 | MAPK14, ATF2, ACTB, ACTG1, ACSL1, NDUFA5, SDHD, ATP5C1 | More | | Loperamide | hsa04720 | Long-term potentiation | 3.98E-06 | 8 | P17252, Q16566, Q13557, P0DP23, P18848, O15399, Q08828, Q14643 | PRKCA, CAMK4, CAMK2D, CALM1, ATF4, GRIN2D, ADCY1, ITPR1 | More | | Loperamide | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Loperamide | hsa04724 | Glutamatergic synapse | 5.91E-03 | 7 | P48058, O15399, Q08828, P51828, P17252, P62873, P15104 | GRIA4, GRIN2D, ADCY1, ADCY7, PRKCA, GNB1, GLUL | More | | Loperamide | hsa04725 | Cholinergic synapse | 4.42E-04 | 8 | Q08828, P51828, P17252, P62873, P18848, Q13557, P31751, P10415 | ADCY1, ADCY7, PRKCA, GNB1, ATF4, CAMK2D, AKT2, BCL2 | More | | Loperamide | hsa04727 | GABAergic synapse | 4.08E-02 | 5 | Q08828, P51828, P62873, P46459, P17252 | ADCY1, ADCY7, GNB1, NSF, PRKCA | More | | Loperamide | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | Loperamide | hsa04740 | Olfactory transduction | 2.61E-02 | 3 | P62873, Q13557, P0DP23 | GNB1, CAMK2D, CALM1 | More | | Loperamide | hsa04744 | Phototransduction | 1.30E-05 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Loperamide | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.34E-06 | 12 | P14778, P01584, Q08828, P51828, Q13557, P19174, P42338, P17252, P24723, Q04759, P0DP23, P01042 | IL1R1, IL1B, ADCY1, ADCY7, CAMK2D, PLCG1, PIK3CB, PRKCA, PRKCH, PRKCQ, CALM1, KNG1 | More | | Loperamide | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Loperamide | hsa04911 | Insulin secretion | 3.47E-02 | 4 | Q08828, P17252, P18848, Q13557 | ADCY1, PRKCA, ATF4, CAMK2D | More | | Loperamide | hsa04912 | GnRH signaling pathway | 5.72E-04 | 9 | P17252, Q08828, P18848, Q13557, Q16539, Q9Y6R4, Q14643, P0DP23, P22694 | PRKCA, ADCY1, ATF4, CAMK2D, MAPK14, MAP3K4, ITPR1, CALM1, PRKACB | More | | Loperamide | hsa04914 | Progesterone-mediated oocyte maturation | 3.26E-02 | 6 | Q08828, P51828, P31751, Q13370, Q9UJX4, P08238 | ADCY1, ADCY7, AKT2, PDE3B, ANAPC5, HSP90AB1 | More | | Loperamide | hsa04915 | Estrogen signaling pathway | 3.28E-03 | 9 | P18848, Q08828, P51828, P31751, P08238, P11142, P0DP23, Q15788, P10415 | ATF4, ADCY1, ADCY7, AKT2, HSP90AB1, HSPA8, CALM1, NCOA1, BCL2 | More | | Loperamide | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | Loperamide | hsa04919 | Thyroid hormone signaling pathway | 5.60E-04 | 6 | P49841, P22694, P60709, P63261, O60244, Q9NVC6 | GSK3B, PRKACB, ACTB, ACTG1, MED14, MED17 | More | | Loperamide | hsa04920 | Adipocytokine signaling pathway | 4.72E-02 | 4 | P33121, Q04759, Q9Y4H2, P01375 | ACSL1, PRKCQ, IRS2, TNF | More | | Loperamide | hsa04921 | Oxytocin signaling pathway | 9.08E-04 | 6 | P0DP23, P17252, Q16566, P60660, P60709, P63261 | CALM1, PRKCA, CAMK4, MYL6, ACTB, ACTG1 | More | | Loperamide | hsa04923 | Regulation of lipolysis in adipocytes | 1.20E-03 | 7 | Q08828, P51828, P07550, Q13370, P42338, Q9Y4H2, P31751 | ADCY1, ADCY7, ADRB2, PDE3B, PIK3CB, IRS2, AKT2 | More | | Loperamide | hsa04925 | Aldosterone synthesis and secretion | 9.45E-07 | 10 | Q14643, P18848, Q08828, P51828, P0DP23, P17252, Q16566, Q13557, P20020, P23634 | ITPR1, ATF4, ADCY1, ADCY7, CALM1, PRKCA, CAMK4, CAMK2D, ATP2B1, ATP2B4 | More | | Loperamide | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Loperamide | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | Loperamide | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.63E-08 | 9 | P84022, Q13485, P01584, P42224, P10415, P31751, P49767, P17252, P19174 | SMAD3, SMAD4, IL1B, STAT1, BCL2, AKT2, VEGFC, PRKCA, PLCG1 | More | | Loperamide | hsa04935 | Growth hormone synthesis, secretion and action | 3.93E-02 | 6 | P19174, Q08828, P51828, P17252, P31751, P42224 | PLCG1, ADCY1, ADCY7, PRKCA, AKT2, STAT1 | More | | Loperamide | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Loperamide | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Loperamide | hsa04966 | Collecting duct acid secretion | 2.32E-03 | 3 | P02730, P00918, Q9Y666 | SLC4A1, CA2, SLC12A7 | More | | Loperamide | hsa04970 | Salivary secretion | 4.80E-06 | 7 | Q08828, P51828, Q14643, P20020, P23634, P17252, P0DP23 | ADCY1, ADCY7, ITPR1, ATP2B1, ATP2B4, PRKCA, CALM1 | More | | Loperamide | hsa04971 | Gastric acid secretion | 2.67E-03 | 4 | P17252, P60709, P63261, P0DP23 | PRKCA, ACTB, ACTG1, CALM1 | More | | Loperamide | hsa04972 | Pancreatic secretion | 7.98E-05 | 7 | Q14643, P20020, P23634, P17252, Q08828, P51828, P62491 | ITPR1, ATP2B1, ATP2B4, PRKCA, ADCY1, ADCY7, RAB11A | More | | Loperamide | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Loperamide | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | | Loperamide | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | Loperamide | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | Loperamide | hsa05014 | Amyotrophic lateral sclerosis | 8.60E-03 | 9 | O15399, P10415, P36542, Q13509, P68371, Q53GS7, P60709, P63261, Q9GZY0 | GRIN2D, BCL2, ATP5C1, TUBB3, TUBB2C, GLE1, ACTB, ACTG1, NXF2; NXF2B | More | | Loperamide | hsa05016 | Huntington disease | 2.46E-05 | 3 | Q9GZM3, P52435, Q9NYC9 | POLR2J2, POLR2J, DNAH9 | More | | Loperamide | hsa05017 | Spinocerebellar ataxia | 3.80E-03 | 8 | P17252, O75460, Q8TB72, O15399, P31751, P28070, P43686, O00232 | PRKCA, ERN1, PUM2, GRIN2D, AKT2, PSMB4, PSMC4, PSMD12 | More | | Loperamide | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Loperamide | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Loperamide | hsa05031 | Amphetamine addiction | 1.35E-03 | 6 | O15399, P0DP23, Q16566, Q13557, P18848, P17252 | GRIN2D, CALM1, CAMK4, CAMK2D, ATF4, PRKCA | More | | Loperamide | hsa05032 | Morphine addiction | 4.08E-02 | 5 | Q08828, P51828, P62873, Q13370, P17252 | ADCY1, ADCY7, GNB1, PDE3B, PRKCA | More | | Loperamide | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Loperamide | hsa05100 | Bacterial invasion of epithelial cells | 8.79E-04 | 3 | P60709, P63261, Q92529 | ACTB, ACTG1, SHC3 | More | | Loperamide | hsa05110 | Vibrio cholerae infection | 3.95E-03 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Loperamide | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.62E-04 | 7 | Q16539, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Loperamide | hsa05131 | Shigellosis | 1.91E-02 | 3 | P60709, P63261, P07384 | ACTB, ACTG1, CAPN1 | More | | Loperamide | hsa05132 | Salmonella infection | 4.75E-08 | 20 | P51617, P01584, P25963, P08238, Q9UJU2, P63261, Q96RF0, Q13546, Q13489, P10415, P08575, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371, P49754, Q9NP90 | IRAK1, IL1B, NFKBIA, HSP90AB1, LEF1, ACTG1, SNAG1, RIPK1, BIRC3, BCL2, PTPRC, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C, VPS41, RAB9B | More | | Loperamide | hsa05133 | Pertussis | 2.88E-07 | 6 | P0DP23, P01584, P23528, P09871, P0C0L4, P51617 | CALM1, IL1B, CFL1, C1S, C4A, IRAK1 | More | | Loperamide | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Loperamide | hsa05135 | Yersinia infection | 5.31E-03 | 8 | P60709, P63261, Q16513, P13612, P06239, Q16539, P01375, P49841 | ACTB, ACTG1, PKN2, ITGA4, LCK, MAPK14, TNF, GSK3B | More | | Loperamide | hsa05140 | Leishmaniasis | 5.06E-05 | 12 | P13612, O75015, P14598, P13765, O60603, P25963, P01375, P29350, P49006, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, HLA-DOB, TLR2, NFKBIA, TNF, PTPN6, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | Loperamide | hsa05143 | African trypanosomiasis | 2.13E-05 | 7 | P01375, P01584, P69905, P68871, P48023, P17252, P01042 | TNF, IL1B, HBA2, HBB, FASLG, PRKCA, KNG1 | More | | Loperamide | hsa05144 | Malaria | 1.12E-05 | 7 | P60033, P69905, P68871, O60603, P01375, P35443, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | Loperamide | hsa05145 | Toxoplasmosis | 7.31E-06 | 10 | P51617, P25963, P10415, Q13489, P23458, P42224, P31751, P11142, P29965, Q13651 | IRAK1, NFKBIA, BCL2, BIRC3, JAK1, STAT1, AKT2, HSPA8, CD40LG, IL10RA | More | | Loperamide | hsa05146 | Amoebiasis | 8.90E-06 | 12 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | Loperamide | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Loperamide | hsa05161 | Hepatitis B | 1.11E-05 | 12 | P17252, P18848, P23458, P25963, Q13485, P31751, P10415, P27348, P84022, P01568, P42224, P51617 | PRKCA, ATF4, JAK1, NFKBIA, SMAD4, AKT2, BCL2, YWHAQ, SMAD3, IFNA21, STAT1, IRAK1 | More | | Loperamide | hsa05162 | Measles | 1.74E-04 | 10 | P51617, P01568, P23458, P42224, P14784, P31751, P11142, P01584, Q9NP90, P10415 | IRAK1, IFNA21, JAK1, STAT1, IL2RB, AKT2, HSPA8, IL1B, RAB9B, BCL2 | More | | Loperamide | hsa05163 | Human cytomegalovirus infection | 2.07E-04 | 22 | P31751, P01375, P62873, P63218, P50151, P0DP23, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, P61073, P17252, Q13651, P25025, Q16539, P18848, O00463, P61769, P01568 | AKT2, TNF, GNB1, GNG5, GNG10, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, CXCR4, PRKCA, IL10RA, CXCR2, MAPK14, ATF4, TRAF5, B2M, IFNA21 | More | | Loperamide | hsa05164 | Influenza A | 7.10E-03 | 3 | P48551, P60709, P63261 | IFNAR2, ACTB, ACTG1 | More | | Loperamide | hsa05168 | Herpes simplex virus 1 infection | 1.97E-06 | 20 | Q9UKJ0, P01568, P01584, Q9UBU9, Q9GZY0, P23458, P42224, Q07955, Q01130, Q13243, Q13489, P51617, P61769, P31751, Q13398, Q6P280, Q03923, Q9UDV6, P10415, Q14232 | PILRB, IFNA21, IL1B, NXF1, NXF2; NXF2B, JAK1, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, IRAK1, B2M, AKT2, ZNF211, ZNF529, ZNF85, ZNF212, BCL2, EIF2B1 | More | | Loperamide | hsa05169 | Epstein-Barr virus infection | 2.54E-02 | 8 | Q92769, P04637, Q13546, P10415, P24522, O60603, P51617, P09693 | HDAC2, TP53, RIPK1, BCL2, GADD45A, TLR2, IRAK1, CD3G | More | | Loperamide | hsa05170 | Human immunodeficiency virus 1 infection | 1.16E-06 | 16 | P31751, P62873, P0DP23, P61073, P17252, Q13546, P61769, Q14643, P01568, P51617, O60603, P19174, P23528, P09693, P10415, Q9Y6Q5 | AKT2, GNB1, CALM1, CXCR4, PRKCA, RIPK1, B2M, ITPR1, IFNA21, IRAK1, TLR2, PLCG1, CFL1, CD3G, BCL2, AP1M2 | More | | Loperamide | hsa05200 | Pathways in cancer | 2.92E-10 | 30 | P23458, P08238, P42224, P19174, Q15311, Q9UJU2, P17252, P43246, Q13485, P14923, P10415, Q13489, P49767, P31751, P25116, Q08828, P51828, P62873, P61073, P78417, O75293, Q15788, P0DP23, Q13557, O43521, P01568, P14784, P16871, P00734, P01042 | JAK1, HSP90AB1, STAT1, PLCG1, RALBP1, LEF1, PRKCA, MSH2, SMAD4, JUP, BCL2, BIRC3, VEGFC, AKT2, F2R, ADCY1, ADCY7, GNB1, CXCR4, GSTO1, GADD45B, NCOA1, CALM1, CAMK2D, BCL2L11, IFNA21, IL2RB, IL7R, F2, KNG1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P0DP23 | CALM1 | Calmodulin-1 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.822 | P0DP24 | CALM2 | Calmodulin-2 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.738 | P0DP23 | CALM1 | Calmodulin-1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.775 | P0DP25 | CALM3 | Calmodulin-3 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.775 | P0DP24 | CALM2 | Calmodulin-2 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.775 | P0DP23 | CALM1 | Calmodulin-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.775 | P0DP25 | CALM3 | Calmodulin-3 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.775 | P0DP24 | CALM2 | Calmodulin-2 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.775 | P0DP23 | CALM1 | Calmodulin-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.744 | P0DP25 | CALM3 | Calmodulin-3 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.744 | P0DP24 | CALM2 | Calmodulin-2 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.744 | P0DP23 | CALM1 | Calmodulin-1 | Q15311 | RALBP1 | RalA-binding protein 1 | 0.858 | P46091 | GPR1 | Chemerin-like receptor 2 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.736 | P0DP23 | CALM1 | Calmodulin-1 | P17252 | PRKCA | Protein kinase C alpha type | -0.776 | P46091 | GPR1 | Chemerin-like receptor 2 | P17252 | PRKCA | Protein kinase C alpha type | 0.741 | P0DP25 | CALM3 | Calmodulin-3 | P17252 | PRKCA | Protein kinase C alpha type | -0.776 | P0DP24 | CALM2 | Calmodulin-2 | P17252 | PRKCA | Protein kinase C alpha type | -0.776 | P0DP23 | CALM1 | Calmodulin-1 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.944 | P46091 | GPR1 | Chemerin-like receptor 2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.838 | P0DP25 | CALM3 | Calmodulin-3 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.944 | P0DP24 | CALM2 | Calmodulin-2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.944 | P0DP23 | CALM1 | Calmodulin-1 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | 0.777 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.809 | P0DP25 | CALM3 | Calmodulin-3 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | 0.777 | P0DP24 | CALM2 | Calmodulin-2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | 0.777 | P0DP23 | CALM1 | Calmodulin-1 | P14923 | JUP | Junction plakoglobin | -0.852 | P46091 | GPR1 | Chemerin-like receptor 2 | P14923 | JUP | Junction plakoglobin | 0.883 | P0DP25 | CALM3 | Calmodulin-3 | P14923 | JUP | Junction plakoglobin | -0.852 | P0DP24 | CALM2 | Calmodulin-2 | P14923 | JUP | Junction plakoglobin | -0.852 | P0DP23 | CALM1 | Calmodulin-1 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.772 | P46091 | GPR1 | Chemerin-like receptor 2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.808 | P0DP25 | CALM3 | Calmodulin-3 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.772 | P0DP24 | CALM2 | Calmodulin-2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.772 | P0DP23 | CALM1 | Calmodulin-1 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.8 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.759 | P0DP25 | CALM3 | Calmodulin-3 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.8 | P0DP24 | CALM2 | Calmodulin-2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.8 | P0DP23 | CALM1 | Calmodulin-1 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.84 | P46091 | GPR1 | Chemerin-like receptor 2 | P49767 | VEGFC | Vascular endothelial growth factor C | 0.718 | P0DP25 | CALM3 | Calmodulin-3 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.84 | P0DP24 | CALM2 | Calmodulin-2 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.84 | P0DP23 | CALM1 | Calmodulin-1 | P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | 0.761 | P46091 | GPR1 | Chemerin-like receptor 2 | P25116 | F2R | Proteinase-activated receptor 1 | 0.76 | P0DP23 | CALM1 | Calmodulin-1 | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.725 | P0DP24 | CALM2 | Calmodulin-2 | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.711 | P0DP23 | CALM1 | Calmodulin-1 | P51828 | ADCY7 | Adenylate cyclase type 7 | 0.719 | P0DP23 | CALM1 | Calmodulin-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.853 | P0DP25 | CALM3 | Calmodulin-3 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.853 | P0DP24 | CALM2 | Calmodulin-2 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.853 | P0DP24 | CALM2 | Calmodulin-2 | P61073 | CXCR4 | C-X-C chemokine receptor type 4 | 0.759 | P0DP23 | CALM1 | Calmodulin-1 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | -0.804 | P46091 | GPR1 | Chemerin-like receptor 2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | 0.738 | P0DP25 | CALM3 | Calmodulin-3 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | -0.804 | P0DP24 | CALM2 | Calmodulin-2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | -0.804 | P0DP23 | CALM1 | Calmodulin-1 | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.853 | P0DP25 | CALM3 | Calmodulin-3 | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.853 | P0DP24 | CALM2 | Calmodulin-2 | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.853 | P0DP24 | CALM2 | Calmodulin-2 | Q15788 | NCOA1 | Nuclear receptor coactivator 1 | 0.731 | P0DP23 | CALM1 | Calmodulin-1 | P0DP23 | CALM1 | Calmodulin-1 | 1 | P46091 | GPR1 | Chemerin-like receptor 2 | P0DP23 | CALM1 | Calmodulin-1 | -0.846 | P0DP25 | CALM3 | Calmodulin-3 | P0DP23 | CALM1 | Calmodulin-1 | 1 | P0DP24 | CALM2 | Calmodulin-2 | P0DP23 | CALM1 | Calmodulin-1 | 1 | P0DP24 | CALM2 | Calmodulin-2 | Q13557 | CAMK2D | Calcium/calmodulin-dependent protein kinase type II subunit delta | 0.786 | P0DP24 | CALM2 | Calmodulin-2 | O43521 | BCL2L11 | Bcl-2-like protein 11 | 0.75 | P0DP23 | CALM1 | Calmodulin-1 | P01568 | IFNA21 | Interferon alpha-21 | -0.852 | P46091 | GPR1 | Chemerin-like receptor 2 | P01568 | IFNA21 | Interferon alpha-21 | 0.724 | P0DP25 | CALM3 | Calmodulin-3 | P01568 | IFNA21 | Interferon alpha-21 | -0.852 | P0DP24 | CALM2 | Calmodulin-2 | P01568 | IFNA21 | Interferon alpha-21 | -0.852 | P0DP23 | CALM1 | Calmodulin-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.801 | P0DP25 | CALM3 | Calmodulin-3 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.801 | P0DP24 | CALM2 | Calmodulin-2 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.801 | P0DP23 | CALM1 | Calmodulin-1 | P16871 | IL7R | Interleukin-7 receptor subunit alpha | 0.718 | P0DP23 | CALM1 | Calmodulin-1 | P00734 | F2 | Prothrombin | -0.738 | P0DP23 | CALM1 | Calmodulin-1 | P01042 | KNG1 | Kininogen-1 | -0.71 | P0DP25 | CALM3 | Calmodulin-3 | P01042 | KNG1 | Kininogen-1 | -0.71 | P0DP24 | CALM2 | Calmodulin-2 | P01042 | KNG1 | Kininogen-1 | -0.71 |
| Loperamide | hsa05202 | Transcriptional misregulation in cancer | 1.90E-05 | 19 | Q15532, P41732, P14780, P27930, P14923, Q16548, P11215, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | SS18, TSPAN7, MMP9, IL1R2, JUP, BCL2A1, ITGAM, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Loperamide | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | | Loperamide | hsa05204 | Chemical carcinogenesis | 2.59E-04 | 4 | P00325, P78417, P11712, P33260 | ADH1B, GSTO1, CYP2C9, CYP2C18 | More | | Loperamide | hsa05206 | MicroRNAs in cancer | 4.07E-02 | 2 | P15311, P63279 | VIL2, UBE2I | More | | Loperamide | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Loperamide | hsa05212 | Pancreatic cancer | 1.26E-04 | 8 | P31751, Q15311, P23458, P42224, P37173, P84022, Q13485, O75293 | AKT2, RALBP1, JAK1, STAT1, TGFBR2, SMAD3, SMAD4, GADD45B | More | | Loperamide | hsa05214 | Glioma | 6.49E-08 | 9 | P0DP23, Q16566, Q13557, P17252, P31751, P04637, P19174, P24522, O75293 | CALM1, CAMK4, CAMK2D, PRKCA, AKT2, TP53, PLCG1, GADD45A, GADD45B | More | | Loperamide | hsa05216 | Thyroid cancer | 1.85E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Loperamide | hsa05217 | Basal cell carcinoma | 4.42E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Loperamide | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | | Loperamide | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | | Loperamide | hsa05225 | Hepatocellular carcinoma | 4.07E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Loperamide | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Loperamide | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.27E-03 | 6 | P42338, P19174, P07766, P20963, P06239, Q04759 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ | More | | Loperamide | hsa05321 | Inflammatory bowel disease | 2.22E-03 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Loperamide | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Loperamide | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Loperamide | hsa05332 | Graft-versus-host disease | 3.34E-03 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Loperamide | hsa05340 | Primary immunodeficiency | 2.68E-02 | 2 | P11912, P07766 | CD79A, CD3E | More | | Loperamide | hsa05410 | Hypertrophic cardiomyopathy | 1.18E-03 | 4 | P26012, P09493, P60709, P63261 | ITGB8, TPM1, ACTB, ACTG1 | More | | Loperamide | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.58E-04 | 5 | P54284, P15924, P26012, P60709, P63261 | CACNB3, DSP, ITGB8, ACTB, ACTG1 | More | | Loperamide | hsa05414 | Dilated cardiomyopathy | 1.73E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Loperamide | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Loperamide | hsa05416 | Viral myocarditis | 8.96E-03 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Loperamide | hsa05418 | Fluid shear stress and atherosclerosis | 4.58E-05 | 14 | Q16539, P14598, P78417, P10599, P14780, P01375, P60709, P63261, P10415, P14778, P27930, P0DP23, P08238, Q92974 | MAPK14, NCF1, GSTO1, TXN, MMP9, TNF, ACTB, ACTG1, BCL2, IL1R1, IL1R2, CALM1, HSP90AB1, ARHGEF2 | More | | |